Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prospects for an SV40 vaccine.

M J Imperiale1, H I Pass, M G Sanda

  • 1Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor 48109-0942, USA. imperial@umich.edu

Seminars in Cancer Biology
|March 13, 2001
PubMed
Summary

Researchers explored using a modified Simian virus 40 (SV40) vaccine to treat SV40-positive mesotheliomas. This novel vaccine demonstrated effectiveness in animal models, offering potential for human mesothelioma treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.

Oncogene·2017
Same author

Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma.

Oncogene·2015
Same author

Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression.

Cell death & disease·2015
Same author

Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation.

Cell death & disease·2014
Same author

Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.

Oncogene·2013

Area of Science:

  • Oncology
  • Virology
  • Immunotherapy

Background:

  • Simian virus 40 (SV40) is implicated as a potential cause of human cancers.
  • SV40-positive mesotheliomas are difficult to treat with current interventions.

Purpose of the Study:

  • To investigate the therapeutic potential of a modified SV40 T antigen vaccine.
  • To evaluate the efficacy of this vaccine against SV40-positive mesotheliomas.

Main Methods:

  • A modified SV40 T antigen, lacking transforming domains, was cloned into a vaccinia virus vector.
  • The engineered vaccinia virus was tested in animal tumor models.

Main Results:

  • The modified SV40 vaccine showed efficacy in preventing tumor development after challenge.
  • The vaccine was also effective in treating pre-existing tumors in the animal models.

Conclusions:

  • A modified SV40 T antigen delivered via a vaccinia virus vector shows promise as a vaccine.
  • This approach holds potential for treating human mesothelioma patients with SV40-positive tumors.

Related Experiment Videos